Medicines Co. (MDCO) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
The Medicines Company Reports First-Quarter 2018 Results
April 25, 2018 7:00 AM EDTPARSIPPANY, N.J.--(BUSINESS WIRE)-- The Medicines Company (NASDAQ: MDCO) today reported its financial results for the first quarter ended March 31, 2018.
During the first quarter of 2018, The Medicines Company continued to demonstrate strong clinical and operational execution, significantly advancing the ORION development programs for our investigational agent, inclisiran, and delivering against all of our other 2018 objectives, said Clive Meanwell, M.D., Ph.D., Chief Executive Officer of The Medicines Company.
First quarter 2018 highlights included:
In January, the Company completed the sale of its infectious disease business unit to Melinta... More